Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, NJ – June 4, 2007 – Genta Incorporated (Nasdaq: GNTA) announced the presentation of results from a Phase 2 clinical trial of its marketed product, Ganite® (gallium nitrate injection), plus rituximab (Rituxan®; Genentech/IDEC) and dexamethasone in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). The data were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Previously published studies have indicated that high doses of gallium nitrate used alone or in
combination with chemotherapy showed preliminary evidence of clinical activity in patients with
Hodgkin’s disease and non-Hodgkin’s lymphoma. Based on these data, investigators at Loyola
University Medical Center sought to incorporate gallium nitrate into a minimally
myelosuppressive “salvage” regimen (called “GaRD”) that was designed to treat patients who
had failed multiple types of standard therapy.

In the GaRD trial, gallium nitrate was administered in combination with rituximab and
dexamethasone. Twenty-two patients with NHL were entered into this study, most of whom had
been refractory to multiple salvage therapies. All patients had failed prior treatment with
rituximab, including 18 of 22 who received rituximab in their last regimen. Overall, 41% of
patients achieved a major objective response, including 8 (36%) with complete or unconfirmed
complete responses and 1 (5%) with a partial response. Two of the major responders had
previously failed a stem cell transplant; both patients remain in sustained remission 14+ and 18+
months after their last relapse. Six other patients achieved stable disease. Five patients
subsequently underwent a stem cell transplant. Of all 22 patients treated with the GaRD
regimen, 46% are alive at a median followup of 17+ months, and
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 Five MinuteClinic walk-in medical clinics ... metropolitan area. Three clinics opened in Memphis ... A fourth clinic will be added in Springfield ... Bartlett is expected to open October 22.  MinuteClinic is ... the United States . The ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 26, 2007 - A new study published ... ("A National Survey of,Physician-Industry Relationships") on the ... the need for,profession-wide and public policy reforms ... that the existing,voluntary PhRMA (Pharmaceutical Research and ...
... 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced today ... of the Journal of Neuroscience a study,by ... National Jewish,Medical and Research Center demonstrating that ... 11207, demonstrated,neuroprotection in an animal model of ...
Cached Medicine Technology:Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3
(Date:9/21/2014)... 21, 2014 Discount-Dress.com, a ... has recently announced its decision to implement a new ... easier for ladies across the world. Furthermore, the company ... for ladies. , The new items come in ... discounted prices, up to 56 percent off. "We are ...
(Date:9/21/2014)... Rancho del Rio, Colorado (PRWEB) September 21, 2014 ... of Vail, Colorado, ten teams of disabled and able-bodied ... hand cycles, and completed a ropes course in pursuit ... Team Challenge from national non-profit World T.E.A.M. Sports, ... to participating athletes who successfully completed the three stage ...
(Date:9/21/2014)... Recently, BambooIndustry.com, an experienced producer of natural ... bamboo panels ( http://www.bambooindustry.com/products/bamboo-panel/ ). The company’s excellent panels ... are available at discounted prices now, from 10 to ... bamboo panels are available in many specifications; they ... of them is finely manufactured by qualified workers. They ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 According to latest ... the highest birth rate since 1966 (10.5 births per 1,000 ... their early 40s has risen steadily by 2 percent per ... births to women aged 50 and over) also rose, the ... there were more than nine times as many first births ...
(Date:9/20/2014)... 2014 Diabetes Protocol , a ... is helping thousands of people learn how to naturally ... pills, or prescriptions has caught the attention of Shane ... currently tens of millions of people in the U.S. ... 2 diabetes, and unfortunately, big pharma makes a killing ...
Breaking Medicine News(10 mins):Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2
... New York University,s Center for Neural Science have identified ... Their findings, which appear in the most recent issue ... light on how amblyopia results from disrupted links between ... results from developmental problems in the brain. When the ...
... HealthDay Reporter , FRIDAY, Sept. 10 (HealthDay News) ... people the willies. And they,re apt to make you feel ... experts say, is valid). Head lice truly are nasty ... and eyelashes of their human hosts and cause the creepiest ...
... United States. A new study published in the journal ... rates than whites. The findings reveal that there is a ... community, and African Americans who distrust hospitals are less likely ... Medical Officer of the New York Blood Center in New ...
... manufacturers and public health decision-makers need to collaborate in ... reduce the likelihood of supply shortages for pediatric vaccines ... doses to increase coverage, according to research published by ... and data analysis. Sheldon H. Jacobson, a professor ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... modest goals for the amount of fruit and vegetables people ... are not even close to reaching those thresholds, health officials ... for Disease Control and Prevention, in 2009, 67.5 percent of ...
... European Meeting (NEEM) will open tomorrow in Riga, Latvia ... agenda during the two-day meeting. "The discussion will ... across Europe will present updates on a variety of ... and functional results in radical prostatectomy, treatment options in ...
Cached Medicine News:Health News:NYU researchers identify new neurological deficit behind lazy eye 2Health News:Back to School Can Mean a Return to Head Lice Worries 2Health News:Back to School Can Mean a Return to Head Lice Worries 3Health News:Pediatric vaccine stockpile policies need to be revisited, researcher says 2Health News:Pediatric vaccine stockpile policies need to be revisited, researcher says 3Health News:Most Americans Still Not Eating Enough Fruits, Veggies 2Health News:Most Americans Still Not Eating Enough Fruits, Veggies 3
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
Sensitive Eyes drops keep soft contact lenses moist....
Lens Plus Sterile Saline Solution...
... Rub formula is the most convenient multi-purpose ... in one bottle without the need to ... lenses and removes protein build-up when used ... contains Hydranate, a special ingredient that removes ...
Medicine Products: